Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DP85ES
|
|||
| Drug Name |
177Lu-labelled DOTA-JR11
|
|||
| Drug Type |
Radiopharmaceutical therapy agent
|
|||
| Indication | Neuroendocrine cancer [ICD-11: 2B72.1; ICD-9: 209] | Phase 1/2 | [1] | |
| Company |
Ipsen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Somatostatin receptor (SSTR) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02592707) Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs. U.S. National Institutes of Health. | |||
| REF 2 | Multimodal Imaging of 2-Cycle PRRT with 177 Lu-DOTA-JR11 and 177 Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model. J Nucl Med. 2021 Mar;62(3):393-398. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.